The Effect of Abobotulinum Toxin A on the Symptoms of Raynaud's Phenomenon

Stopped early · Phase 4 · Has a placebo group

Conditions studied: Raynaud Phenomenon

In brief

This study aims to investigate the effect of abobotulinum toxin A on the symptoms of Raynaud's phenomenon.

Key facts

Study ID

NCT03639766

Run by

University of Central Florida

People needed

3

Starts

2018-08-31

Expected to finish

2020-01-31

Last updated by the study team

2021-06-30

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Male or female adult between 18 and 80 years of age
• Must have health insurance
• Must have a current diagnosis of Raynaud's phenomenon

You may not qualify if…

• Allergy to abobotulinum toxin A or its components
• Diagnosis of myasthenia gravis
• Previously received abobotulinum toxin vaccine
• Previously undergone upper extremity vascular surgery (including surgical sympathectomy)
• Currently receiving aminoglycoside antibiotics
• Received abobotulinum toxin A treatment in either hand in the past 6 months
• Pregnant women
• Women currently breastfeeding
• Current tobacco smoker (use in the past 12 months)
• Unable to read and speak English
• Adults unable to consent
• Individuals who are not yet adults (infants, children, teenagers)
• Prisoners

Where it is running

• UCF Health Lake Nona Office — Orlando, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.